Core Insights - Alibaba Health reported a revenue of 30.598 billion yuan for the fiscal year 2025, marking a year-on-year growth of 13.2% and a net profit of 1.432 billion yuan, up 62.2% [1][2] - The company's revenue structure is primarily driven by its pharmaceutical e-commerce business, with self-operated pharmaceutical revenue reaching 26.124 billion yuan, a 10.0% increase, while the e-commerce platform revenue surged by 54.0% to 3.588 billion yuan [1][3] - The healthcare and digital services segment saw a decline in revenue, dropping 7.6% to 0.885 billion yuan, attributed to the optimization of certain innovative businesses [3] Revenue Growth - The internet healthcare market in China reached a total market size of 376.4 billion yuan in 2023, reflecting a year-on-year growth of 21.34% [2] - Alibaba Health's revenue surpassed 30 billion yuan for the first time, and its net profit exceeded 1 billion yuan for the first time, achieving significant growth for three consecutive years [2] Competitive Landscape - The internet healthcare sector is experiencing intensified competition, with new entrants and evolving business models impacting traditional players like Alibaba Health [4][5] - The rise of instant retail channels is seen as a key driver for growth in the pharmaceutical retail sector, with predictions indicating a sales scale of 48.7 billion yuan for instant retail in 2024, a 31.3% increase from 2023 [5] - Alibaba Health's business primarily focuses on B2C and B2B, maintaining high levels of next-day delivery service while expanding its reach to 13 cities [5] Innovation and Technology - Alibaba Health is actively integrating new technologies, including AI, into its services, with initiatives like the launch of an AI-assisted traditional Chinese medicine diagnostic system [6][7] - The company has partnered with the China Anti-Cancer Association to enhance cancer prevention and treatment awareness through AI technology [7]

Core Insights - Alibaba Health (00241) reported a revenue of RMB 30.598 billion for the fiscal year ending March 31, 2025, representing a year-on-year increase of 13.2% [1] - Adjusted net profit reached RMB 1.95 billion, up 35.6% year-on-year, while profit attributable to the parent company was RMB 1.432 billion, reflecting a significant increase of 62.14% [1] - The company experienced stable growth in its Tmall Health platform, with annual GMV maintaining robust growth and active user numbers continuing to rise [1] Revenue and Profitability - Total revenue for the reporting period was RMB 30.598 billion, marking a 13.2% increase year-on-year [1] - Net profit for the period was RMB 1.432 billion, showing a year-on-year growth of 62.2% [1] - Adjusted net profit amounted to RMB 1.95 billion, with an adjusted net profit margin increasing from 5.3% to 6.4% [1] Business Development - The Tmall Health platform's advertising business saw rapid growth, enhancing merchants' operational capabilities and brand service [1] - The company is actively exploring AI applications in the medical service sector to improve efficiency and process quality [1] User Engagement and Logistics - The effective GMV from online self-operated stores showed healthy growth, with active user numbers and self-operated membership continuing to rise [2] - The number of self-operated SKUs increased by 33.6% year-on-year to 1.23 million [2] - The company has optimized its pharmaceutical logistics network, maintaining high levels of next-day delivery service, which is expanding to cover 13 cities [2]

阿里健康(00241.HK)2025财年全年营收305.98亿元，上年同期270.26亿元。 ...

智通财经5月19日电，阿里健康2024年营收306.0亿元人民币，预估302.7亿元人民币；调整后净利润19.5 亿元人民币；毛利率24.3％，预估24.1％。 ...

Core Insights - Alibaba Health announced a stable revenue growth for the fiscal year ending March 31, 2025, with total revenue reaching 30.598 billion RMB, representing a year-on-year increase of 13.2% [1] - The net profit for the reporting period was 1.432 billion RMB, showing a significant year-on-year growth of 62.2% [1] - Adjusted net profit amounted to 1.95 billion RMB, reflecting a year-on-year increase of 35.6%, with the adjusted net profit margin rising from 5.3% to 6.4% [1] Business Performance - The Tmall Health platform continued to develop steadily, with annual GMV maintaining robust growth [1] - The number of active users on the platform continued to increase during the reporting period [1]

Financial Performance - Total revenue for the fiscal year ending March 31, 2025, reached RMB 30,598.3 million, representing a year-on-year growth of 13.2%[4] - Net profit for the same period was RMB 1,432.0 million, showing a significant increase of 62.2% compared to the previous year[4] - Adjusted net profit amounted to RMB 1,949.7 million, reflecting a year-on-year growth of 35.6%, with the adjusted net profit margin rising from 5.3% to 6.4%[4] - Gross profit rose by 26.1% to RMB 7,432.1 million, with a gross margin of 24.3% compared to 21.8% in the prior year[21] - The adjusted net profit for the fiscal year was RMB 1,949.7 million, a 35.6% increase from RMB 1,437.9 million in the previous year[21] - The net profit attributable to the parent company for the year was RMB 1,432,427 thousand, a significant increase of 62.1% compared to RMB 883,477 thousand in 2024[52] - Basic earnings per share increased to RMB 8.91 from RMB 6.29, reflecting a growth of 41.6%[52] - The group's profit before tax for 2025 was RMB 1,432,427,000, a significant increase of 62.2% compared to RMB 883,477,000 in 2024[73] Revenue Breakdown - Revenue from the pharmaceutical self-operated business reached RMB 26,124,420,000, growing by 10.0% year-on-year, driven by an expanded product range and improved user experience[23] - Revenue from the pharmaceutical e-commerce platform business totaled RMB 3,588,499,000, reflecting a significant increase of 54.0% year-on-year[24] - Revenue from healthcare and digital services decreased by 7.5% to RMB 885,373 from RMB 957,838 in 2024[63] User Engagement and Growth - The annual active user count on the Tmall Health platform continued to increase, contributing to a healthy growth in GMV (Gross Merchandise Volume)[8] - The number of online main merchants on the Tmall Health platform grew by 35% year-on-year to 48,300, while the number of SKUs increased by over 91% to 133 million[8] - The self-operated SKU count rose by 33.6% to 1.23 million, enhancing user experience for chronic disease patients[9] - The annual GMV of the Tmall Health platform increased significantly, with active online merchants growing by 35% to 48,300 and online SKUs rising over 91% to 133 million as of March 31, 2025[12] Operational Efficiency and Technology - The company is actively exploring AI applications in healthcare, aligning with national policies to enhance efficiency and service quality in the healthcare sector[7] - The group is committed to building a smart healthcare ecosystem by integrating AI technology with comprehensive pharmaceutical services[20] - The company is committed to leveraging digital technology and operations to provide accessible and efficient healthcare services to millions of families[10] Healthcare Services and Initiatives - The company has signed contracts with nearly 240,000 healthcare professionals to provide online health consultation services[10] - The group expanded its internet hospital services, successfully diversifying into multiple specialties, enhancing patient management and education[16] - The group actively engaged in social responsibility initiatives, providing medical support to vulnerable groups across 31 provinces and regions in China[19] Financial Position and Cash Flow - Cash and cash equivalents as of March 31, 2025, were RMB 2,218,296,000, a decrease from RMB 3,490,169,000 as of March 31, 2024[38] - Net cash flow from operating activities for the year ended March 31, 2025, was RMB 1,395,033,000, compared to RMB 1,079,832,000 in 2024, representing an increase of 29.2%[39] - Net cash used in investing activities was RMB 2,596,482,000 for the year ended March 31, 2025, down from RMB 4,880,900,000 in 2024, indicating a reduction of 46.7%[41] - Net cash used in financing activities was RMB 72,517,000 for the year ended March 31, 2025, compared to RMB 1,982,395,000 in 2024, showing a significant decrease of 96.3%[42] - The company had no outstanding borrowings as of March 31, 2025, maintaining a capital debt ratio of zero[43] Employee and Corporate Governance - The total employee cost for the year was RMB 1,067.9 million, slightly down from RMB 1,097.3 million in the previous year[47] - The company adopted the 2024 Share Award Scheme, which is similar in major aspects to the 2014 Share Award Scheme, ensuring consistency in share reward practices[47] - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance shareholder value[82] - The board has confirmed compliance with the standard code for securities trading during the reporting period[83] Other Financial Information - The company reported no significant investments, acquisitions, or disposals of subsidiaries during the reporting period[49] - The company does not have any significant contingent liabilities or pledged assets as of March 31, 2025[44] - The company had no revenue from any single external customer accounting for 10% or more of total revenue for the year ended March 31, 2025[62] - The company has not experienced any impact on its financial position or performance due to the recent accounting standard amendments[59] - The company has chosen not to disclose remaining performance obligations due to their short-term nature[66]

恒指低开0.81%，报23156.27点；恒生科技指数跌1.02%。阅文集团跌4.7%，阿里健康、阿里巴巴跌超 2.8%，京东健康跌2.1%。 ...

港股科技股拉升，腾讯音乐(01698.HK)涨超10%，京东健康(06618.HK)涨6.45%，阿里健康(00241.HK)、 京东(09618.HK)涨超4%，美团(03690.HK)涨超3%。 ...

港股互联网医疗股盘中回暖，京东健康(06618.HK)涨超3%，阿里健康(00241.HK)涨超2.5%，平安好医 生(01833.HK)、叮当健康(09886.HK)均涨1.5%。 ...

Group 1 - The Hong Kong stock market opened with the Hang Seng Index rising by 2.24% and the Tech Index increasing by 2.72% [1] - Kuaishou (01024.HK) and Longfor Group (00960.HK) both opened more than 5% higher, indicating strong investor interest [1] - Alibaba Health (00241.HK) opened over 4% higher, while Meituan (03690.HK) opened nearly 4% higher, reflecting positive market sentiment towards these companies [1]